Literature DB >> 19478860

Age distribution of patients presenting with uveitis.

Holger Baatz1, Gábor B Scharioth, Diego de Ortueta, Mitrofanis Pavlidis.   

Abstract

BACKGROUND: Endogenous uveitis has long been considered to be uncommon in elderly patients. Recently, population-based studies have shown an increase in the incidence of uveitis with inreasing age. It was the aim of this study to analyse the age distribution of patients presenting with endogenous uveitis in the setting of an eye centre.
METHODS: Retrospective cohort analysis.
RESULTS: 278 patients with endogenous uveitis showed the following age distribution: 0 - 15: 9, 15 - 30: 28, 30 - 45: 73, 45 - 60: 78, >60: 90 (age group: number of patients). Localization of uveitis was 82,4% anterior, 9,4% intermedia, 12,9% posterior. Two patients >60y were diagnosed with a masquerade syndrome.
CONCLUSIONS: A large number of patients presenting with endogenous uveitis is in the elderly age group. An early and appropriate diagnostic work-up for uveitis is recommended for the elderly.

Entities:  

Year:  2007        PMID: 19478860      PMCID: PMC2605695          DOI: 10.2174/1874364100701010023

Source DB:  PubMed          Journal:  Open Ophthalmol J        ISSN: 1874-3641


  10 in total

1.  Epidemiology of uveitis. Incidence and prevalence in a small urban community.

Authors:  R W DARRELL; H P WAGENER; L T KURLAND
Journal:  Arch Ophthalmol       Date:  1962-10

Review 2.  Uveitis in the elderly--is it easy to identify the masquerade?

Authors:  P Zamiri; S Boyd; S Lightman
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

3.  [Uveitis in the elderly].

Authors:  C Favre; V T Tran; C P Herbort
Journal:  Klin Monbl Augenheilkd       Date:  1994-05       Impact factor: 0.700

4.  Characteristics of uveitis presenting for the first time in the elderly.

Authors:  K Chatzistefanou; N N Markomichelakis; W Christen; M Soheilian; C S Foster
Journal:  Ophthalmology       Date:  1998-02       Impact factor: 12.079

5.  Uveitis in the elderly: epidemiological data from the National Long-term Care Survey Medicare Cohort.

Authors:  Sherman W Reeves; Frank A Sloan; Paul P Lee; Glenn J Jaffe
Journal:  Ophthalmology       Date:  2006-01-10       Impact factor: 12.079

6.  Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study.

Authors:  David C Gritz; Ira G Wong
Journal:  Ophthalmology       Date:  2004-03       Impact factor: 12.079

7.  Uveitis presenting de novo in the elderly.

Authors:  K Barton; C E Pavesio; H M Towler; S Lightman
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

Review 8.  [Characteristics of uveitis presenting de novo in the elderly].

Authors:  O Kirsch; M Lautier-Frau; M Labetoulle; H Offret; E Frau
Journal:  J Fr Ophtalmol       Date:  2003-09       Impact factor: 0.818

9.  Uveitis in older patients.

Authors:  T A Makley; R G Orlando
Journal:  Ann Ophthalmol       Date:  1982-10

Review 10.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

  10 in total
  2 in total

1.  High prevalence of anelloviruses in vitreous fluid of children with seasonal hyperacute panuveitis.

Authors:  Saskia L Smits; Anu Manandhar; Freek B van Loenen; Marije van Leeuwen; G Seerp Baarsma; Netty Dorrestijn; Albert D M E Osterhaus; Todd P Margolis; Georges M G M Verjans
Journal:  J Infect Dis       Date:  2012-04-05       Impact factor: 5.226

2.  Risk of a subsequent diagnosis of inflammatory bowel disease in subjects with ophthalmic disorders associated with inflammatory bowel disease: a retrospective cohort analysis of UK primary care data.

Authors:  Dominic King; Joht Singh Chandan; Tom Thomas; Alastair K Denniston; Tasanee Braithwaite; Krishnarajah Niranthrankumar; Raoul Reulen; Nicola Adderley; Nigel J Trudgill
Journal:  BMJ Open       Date:  2022-05-11       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.